Most device channel programs are built for the first look — the sales pitch, the launch deck, the quarter. But channel programs get a second look, and it comes from people with different incentives: a regulator with a complaint file, an acquirer’s diligence team, a health system’s procurement and compliance review. Programs built only for the first look tend not to survive the second.
Why channel is where device compliance problems concentrate
A manufacturer’s own sales force operates inside the company’s training, claims discipline, and legal review. A channel — independent reps, distributors, marketing organizations — operates outside it, while still speaking in the manufacturer’s name. Every layer between the company and the clinician is a layer where an approved claim can drift, a payment can take an unapproved shape, and a relationship can form that nobody documented.
OIG enforcement in healthcare consistently produces settlements in the hundreds of millions of dollars annually, with persistent attention to physician arrangements. The Sunshine Act’s expanded reporting categories have raised the documentation burden on life-sciences commercial teams precisely because the government decided these relationships warrant a permanent public record. The trend line is not subtle: arrangements with prescribers and purchasers are presumed interesting until documented otherwise.
The four structural questions every channel program must answer
1. How is the channel paid — and does the structure match the product’s reimbursement?
The threshold discipline: compensation that varies with the volume or value of federally reimbursed business invites Anti-Kickback scrutiny that fixed, fair-market-value arrangements do not. A program that wants performance-based economics needs to know, line by line, where its products’ reimbursement actually comes from — and structure each line accordingly rather than averaging the risk across the portfolio. (We’ve written a fuller framework on this in how to pay a healthcare sales force.)
2. Who controls the claims?
The manufacturer substantiates and approves claims; the channel repeats them — exactly, and only. That rule has to be contractual, trained, and auditable. A channel free to “localize” messaging is a channel generating off-label and unsubstantiated-claim exposure in the manufacturer’s name, one enthusiastic email at a time. Approved-claims discipline is also where FDA promotional rules and FTC advertising standards meet: the contract should oblige the channel to use approved materials, and the program should periodically verify that it does.
3. Are provider relationships structured for fair market value and documented purpose?
Advisory boards, training engagements, speaker programs, and KOL relationships are legitimate commercial tools — when the compensation is fair market value for services actually needed and actually rendered, and when the documentation says so before the payment moves. The pattern enforcement actions punish is the same every time: payments styled as consulting that track purchasing instead of services. The defense is built in advance or not at all: FMV benchmarking on file, agendas and attendance records kept, deliverables named in the agreement.
4. What does the paper trail prove?
Run the test from the second look backward. If a diligence team pulled your channel file tomorrow, would it show: written agreements for every active relationship; the compensation model and its rationale; FMV documentation where fixed fees apply; attribution records connecting payments to services; Sunshine Act reporting that reconciles with the payments actually made? Each gap in that file is a finding waiting to be written — and in an acquisition, each finding has a purchase-price consequence.
A channel program is not compliant because nobody has complained. It is compliant because the file would survive the complaint.
The payoff is commercial, not just defensive
Health-system buying processes have grown more complex every year, and procurement teams increasingly ask channel-integrity questions directly: who represents you, how are they paid, who controls their claims. Manufacturers that can answer in one page — because the program was designed that way — move through vendor review faster than competitors who have to assemble the answer. The same file that protects you in an audit accelerates you in a sale. Compliance discipline, properly built, is a market-access asset.
Where to start
Not with a policy binder. Start with an inventory: every channel relationship, its contract status, its compensation model, the reimbursement status of the products it touches, and the location of its FMV documentation. The inventory usually takes days, not months — and it converts “we should look at our channel” from an anxiety into a work plan with names and dates on it.
This article represents the professional opinion of GCX Health Inc. and does not constitute legal advice. The Anti-Kickback Statute, FDA promotional rules, and Sunshine Act reporting requirements are fact-specific; engage qualified counsel before structuring or restructuring channel arrangements.